Home
News
Create
Screeners
Insights
Mahamaya Lifesciences
182.
00
-4.00
(-2.15%)
Market Cap
₹425.94 Cr
PE Ratio
33.63
Industry
Chemicals
Buy
Sell
Company Performance:
1D
-2.15%
1M
+17.12%
6M
+56.90%
1Y
+56.90%
5Y
+56.90%
View Company Insights
Latest news about Mahamaya Lifesciences
Mahamaya Lifesciences Limited Exempt from Corporate Governance Compliance Due to BSE SME Listing
Apr 15, 2026
Mahamaya Lifesciences Limited has notified BSE Limited about its exemption from corporate governance compliance requirements under SEBI regulations. The company's listing on the BSE SME platform qualifies it for exemption under Regulation 15(2)(b), relieving it from filing quarterly, half-yearly, and yearly corporate governance reports as required under Regulation 27(2) of SEBI (LODR) Regulations, 2015.
Mahamaya Lifesciences Files Quarterly Compliance Certificate for Q4FY26 Under SEBI Regulations
Apr 04, 2026
Mahamaya Lifesciences Confirms No Share Encumbrance by Promoters in FY26
Apr 03, 2026
Mahamaya Lifesciences Extends IPO Proceeds Utilisation Timeline to March 2028
Mar 10, 2026
Mahamaya Lifesciences Withdraws from Arihant Capital Virtual Conference Due to Scheduling Constraints
Mar 09, 2026
More news about Mahamaya Lifesciences
22
Jan 26
Mahamaya Lifesciences Limited Receives 'Company of the Year – Medium Scale' Award at ICSCE 2026, Dubai
Mahamaya Lifesciences Limited received the 'Company of the Year – Medium Scale' award at ICSCE 2026 in Dubai on January 20, 2026, presented by PMFAI. The company disclosed this achievement under SEBI Regulation 30 on January 22, 2026, highlighting its excellence in the pharmaceutical sector and compliance with regulatory requirements.
17
Dec 25
Vijay Kedia Acquires 8.91 Lakh Shares in Mahamaya Lifesciences at ₹140 Per Share
Investor Vijay Kedia has purchased 8.91 lakh shares of Mahamaya Lifesciences, an SME-listed agro chemicals company, at ₹140 per share. The total investment amounts to ₹12.47 crores, representing a substantial stake in the small-cap firm. This move has drawn attention to the company and the agro chemicals sector.
02
Dec 25
Mahamaya Lifesciences Reports 17.6% Profit Growth in H1 FY26
Mahamaya Lifesciences, a provider of agricultural crop protection solutions, announced unaudited financial results for H1 FY26. Revenue from operations increased by 11.5% to ₹16,306.37 lakhs. Standalone profit rose by 17.6% to ₹852.56 lakhs. Earnings per share improved by 7.1% to ₹4.80. The results were approved by the Board of Directors on December 02, 2025. The company's performance indicates strong market position and increasing demand for its products in the agricultural sector.
Mahamaya Lifesciences
182.
00
-
4.
00
(-
2.
15
%)
1 Year Returns:
+56.90%
Industry Peers
UPL
641.85
(-
0.
35
%)
PI Industries
3,054.80
(-
1.
17
%)
Bayer Crop Science
4,764.10
(+
1.
71
%)
Sumitomo Chemical
419.15
(-
3.
95
%)
Sharda Cropchem
1,072.75
(-
6.
77
%)
Rallis
265.91
(+
1.
21
%)
Dhanuka Agritech
1,079.65
(+
2.
25
%)
NACL Industries
161.32
(+
1.
20
%)
Bhagiradha Chemicals & Industries
264.91
(-
1.
23
%)
Bharat Rasayan
1,384.70
(+
0.
27
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO